CN119730867A - 用于抑制rho激酶的组合物和方法 - Google Patents

用于抑制rho激酶的组合物和方法 Download PDF

Info

Publication number
CN119730867A
CN119730867A CN202380032652.0A CN202380032652A CN119730867A CN 119730867 A CN119730867 A CN 119730867A CN 202380032652 A CN202380032652 A CN 202380032652A CN 119730867 A CN119730867 A CN 119730867A
Authority
CN
China
Prior art keywords
cancer
derivative
subject
disease
tissue
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202380032652.0A
Other languages
English (en)
Chinese (zh)
Inventor
Y·秦
N·巴拉克
J·金
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Interlude Biopharmaceutical Co
University of Maryland, College Park
Original Assignee
Interlude Biopharmaceutical Co
University of Maryland, College Park
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Interlude Biopharmaceutical Co, University of Maryland, College Park filed Critical Interlude Biopharmaceutical Co
Publication of CN119730867A publication Critical patent/CN119730867A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0046—Ear
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Otolaryngology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CN202380032652.0A 2022-02-09 2023-02-09 用于抑制rho激酶的组合物和方法 Pending CN119730867A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263308330P 2022-02-09 2022-02-09
US63/308,330 2022-02-09
PCT/US2023/062247 WO2023154770A1 (en) 2022-02-09 2023-02-09 Compositions and methods for inhibiting rho kinase

Publications (1)

Publication Number Publication Date
CN119730867A true CN119730867A (zh) 2025-03-28

Family

ID=87565095

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202380032652.0A Pending CN119730867A (zh) 2022-02-09 2023-02-09 用于抑制rho激酶的组合物和方法

Country Status (6)

Country Link
US (1) US20250144166A1 (cg-RX-API-DMAC7.html)
EP (1) EP4475867A4 (cg-RX-API-DMAC7.html)
JP (1) JP2025506487A (cg-RX-API-DMAC7.html)
CN (1) CN119730867A (cg-RX-API-DMAC7.html)
CA (1) CA3243960A1 (cg-RX-API-DMAC7.html)
WO (1) WO2023154770A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118873629B (zh) * 2024-09-27 2024-12-10 北京大学口腔医学院 醋酸拉唑肽在制备促进成骨药物中的用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009047532A2 (en) * 2007-10-12 2009-04-16 Cancer Research Technology Limited Cancer susceptibility loci
WO2009132050A2 (en) * 2008-04-21 2009-10-29 Otonomy, Inc. Auris formulations for treating otic diseases and conditions
JP2020507626A (ja) * 2017-02-10 2020-03-12 イノベイト バイオファーマシューティカルズ インコーポレイテッド 腸上皮の透過性と関連する疾患を治療する組成物及び方法
WO2019183036A1 (en) * 2018-03-19 2019-09-26 Innovate Biopharmaceuticals, Inc. Compositions and methods for potentiating immune checkpoint inhibitor therapy
KR20220049005A (ko) * 2019-08-16 2022-04-20 9 미터스 바이오파마, 인코포레이티드 라라조타이드 제형
AU2021255955A1 (en) * 2020-04-15 2022-11-10 Interlude Biopharma Co. Larazotide derivatives comprising d-amino acids

Also Published As

Publication number Publication date
WO2023154770A1 (en) 2023-08-17
EP4475867A1 (en) 2024-12-18
JP2025506487A (ja) 2025-03-11
CA3243960A1 (en) 2023-08-17
EP4475867A4 (en) 2026-02-18
US20250144166A1 (en) 2025-05-08

Similar Documents

Publication Publication Date Title
ES2459018T3 (es) Formulaciones de efectores de la unión estrecha
CN106661094B (zh) 骨形态发生蛋白的治疗用途
CN114224889B (zh) 西奥罗尼联合免疫检查点抑制剂在抗肿瘤治疗中的应用
CN103608029A (zh) 包含阿柏西普、亚叶酸、5-氟尿嘧啶(5-fu)和伊立替康(folfiri)的组合物
Parrasia et al. Targeting pancreatic ductal adenocarcinoma (PDAC)
WO2023114984A1 (en) Tead inhibitors and uses thereof
CN116529255A (zh) 具有抗癌活性的adp-核糖结合肽及其用途
MG Saez Treatment directed to signalling molecules in patients with advanced differentiated thyroid cancer
CN114514031A (zh) 拉拉唑肽制剂
US20250144166A1 (en) Compositions and methods for inhibiting rho kinase
JP7502832B2 (ja) 膵癌細胞の浸潤転移抑制剤
Han et al. BMP9‐induced vascular normalisation improves the efficacy of immunotherapy against hepatitis B virus‐associated hepatocellular carcinoma
Samanta et al. Zolbetuximab for unresectable and metastatic gastric and gastroesophageal junction adenocarcinoma: a review of literature
CN115956078A (zh) Akt3调节剂及其使用方法
KR20230005209A (ko) D-아미노산을 포함하는 라라조타이드 유도체
CN114514025A (zh) 新颖的治疗
EP4489756A1 (en) Methods of treating small cell lung cancer
Di Paolo et al. Clinical pharmacokinetics of irinotecan-based chemotherapy in colorectal cancer patients
CN110025617A (zh) 双去甲基汉防己甲素双甲酸乙酯与酪氨酸激酶抑制剂的药物组合物
TWI822897B (zh) 一種抗pd-1抗體和法米替尼聯合在製備治療腫瘤的藥物中的用途
AU2014225496B2 (en) Kits and methods for the treatment of cancer using gliadin peptides
Li et al. Treating rheumatoid arthritis using fibroblast-activated protein-α-responsive micelles through a cascade control program
Zhao et al. Zolbetuximab combined with chemotherapy in a patient with CLDN18. 2-positive advanced gastric cancer undergoing hemodialysis: a case report
US20240009252A1 (en) Compositions and methods of treatment comprising tumor-targeting bacteria and chemotherapy or immunotherapy agent
Dayanc et al. Challenges in First-Line Osimertinib Therapy in EGFR-Mutant Non-small Cell Lung Cancer: Acquired Resistance Is

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination